TABLE 1

Study features and baseline and follow-up characteristics of cohort members who were nondiabetic at the baseline examination, SAHS, MCDS, and IRAS

VariableSAHS (7.5-years follow-up)*
MCDS (6.5-years follow-up)*
IRAS (5-years follow-up)*
NHWHAMXNHWAAHA
n54910391,336277224149
M/F (%)45.5/54.540.5/59.541.8/58.249.8/50.239.3/60.745.0/55.0
NGT/IGT (%)91.6/8.484.4/15.690.0/10.067.5/32.566.5/33.568.5/31.5
Age (years)43.8 ± 10.643.1 ± 10.746.0 ± 8.155.3 ± 8.454.2 ± 8.753.8 ± 8.7
Body weight (kg)75.8 ± 16.175.1 ± 15.768.6 ± 11.280.3 ± 15.683.1 ± 17.072.8 ± 14.7
BMI (kg/m2)26.1 ± 4.628.5 ± 5.627.9 ± 4.227.5 ± 5.029.0 ± 5.627.3 ± 4.7
Fasting glucose (mg/dl)84.8 ± 11.086.1 ± 10.284.0 ± 11.798.6 ± 10.799.8 ± 10.794.6 ± 9.9
2-h glucose (mg/dl)97.3 ± 31.1108.2 ± 32.2101.3 ± 29.0122.5 ± 33.0125.1 ± 33.2120.4 ± 33.8
Fasting insulin (IU/ml)11.3 ± 12.614.5 ± 14.715.2 ± 14.117.1 ± 12.518.9 ± 10.918.9 ± 12.6
2-h insulin (lU/ml)66.0 ± 75.3102.1 ± 96.891.4 ± 77.676.9 ± 73.697.2 ± 78.199.4 ± 82.2
Triglycerides (mg/dl)128.2 ± 98.5146.4 ± 97.6203.0 ± 140.7136.0 ± 80.7100.0 ± 53.5151.7 ± 94.9
Mean follow-up time (year)7.6 ± 0.47.4 ± 0.46.4 ± 0.55.3 ± 0.35.3 ± 0.45.2 ± 0.3
Cumulative diabetes incidence (%)6.613.04.816.616.516.8
  • *

    * Indicates follow-up period of the individual cohorts (total n = 3,574, 343 events over 23,805 person-years of follow-up). Data are proportions or mean ± SD. AA, African American; HA, Hispanic American; MX, Mexican; NHW, non-Hispanic white.